Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: <scp>Case‐report</scp>, literature review, and French pharmacovigilance data

Moutel, Marin; Noël, V.; Jary, Aude; Lê, Quoc-Hung; Lier, Clément; Viguier, Manuelle; Lebbe, Célèste; Azzouz, Brahim; Bani‐Sadr, Firouzé

doi:10.1002/ajh.26398

Cited by 3 publications

(2 citation statements)

References 9 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are 6 reported cases of iatrogenic KS induced by JAK inhibitors. 5 , 6 , 7 , 8 , 9 , 10 Four patients were treated with ruxolitinib, 5 , 6 , 7 , 8 1 with baricitinib, 9 and 1 with tofacitinib. 10 The main characteristics of patients are presented in Table I .…”

Section: Discussionmentioning

confidence: 99%

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis

Fournier¹,

Sauder²,

Kamil³

et al. 2023

JAAD Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis

Fournier¹,

Sauder²,

Kamil³

et al. 2023

JAAD Case Reports

View full text Add to dashboard Cite

“…An interesting finding emerges from some case reports linking JAKi therapy to the development of Kaposi sarcoma [ 36 , 37 ]. This phenomenon is probably related to the absolute decrease in CD4 and/or CD8 cell counts and the impairment of natural killer cell function induced by ruxolitinib, which could favor the reactivation of latent human herpes virus 8 or its acquisition [ 36 ].…”

Section: Targeted Therapiesmentioning

confidence: 99%

Skin Malignancies Due to Anti-Cancer Therapies

Starace,

Rapparini,

Cedirian

2024

Cancers

View full text Add to dashboard Cite

Skin cancers involve a significant concern in cancer therapy due to their association with various treatment modalities. This comprehensive review explores the increased risk of skin cancers linked to different anti-cancer treatments, including classic immunosuppressants such as methotrexate (MTX), chemotherapeutic agents such as fludarabine and hydroxyurea (HU), targeted therapies like ibrutinib and Janus Kinase inhibitors (JAKi), mitogen-activated protein kinase pathway (MAPKP) inhibitors, sonic hedgehog pathway (SHHP) inhibitors, and radiotherapy. MTX, a widely used immunosuppressant in different fields, is associated with basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and cutaneous melanoma (CM), particularly at higher dosages. Fludarabine, HU, and other chemotherapeutic agents increase the risk of non-melanoma skin cancers (NMSCs), including cSCC and BCC. Targeted therapies like ibrutinib and JAKi have been linked to an elevated incidence of NMSCs and CM. MAPKP inhibitors, particularly BRAF inhibitors like vemurafenib, are associated with the development of cSCCs and second primary melanomas (SPMs). SHHP inhibitors like vismodegib have been linked to the emergence of cSCCs following treatment for BCC. Additionally, radiotherapy carries carcinogenic risks, especially for BCCs, with increased risks, especially with younger age at the moment of exposure. Understanding these risks and implementing appropriate screening is crucial for effectively managing patients undergoing anti-cancer therapies.

show abstract

Ruxolitinib

2022

Reactions Weekly

View full text Add to dashboard Cite

Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case‐report, literature review, and French pharmacovigilance data

Cited by 3 publications

References 9 publications

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis

Kaposi sarcoma in a patient treated with upadacitinib for rheumatoid arthritis

Skin Malignancies Due to Anti-Cancer Therapies

Ruxolitinib

Contact Info

Product

Resources

About